Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelabresib DDI Study in Advanced Malignancies
NCT07340190Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Primary completion
- Mar 2028
- Countries
- 3
01
Overview
Phase 1, open-label trial of pelabresib in advanced cancer (2 arms), sponsored by Novartis. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Concentration and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
pelabresib
03
Conditions
advanced cancer
Beyond the preview
Go deeper on NCT07340190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340190.